FDA Approves WELIREG Plus LENVIMA for Certain Previously Treated Adult Patients With Advanced Renal Cell Carcinoma With a Clear Cell Component (ccRCC) ...
The Option Award and RSU Award were each granted as of September 28, 2026 (the “Grant Date”) in accordance with Nasdaq Listing Rule 5635(c)(4) and not pursuant to Arvinas’ stock incentive plan. The ...
Arcus Biosciences is a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules for the treatment of cancer and inflammatory diseases. In partnership with ...
AstraZeneca’s supplemental Biologics License Application for Imfinzi in combination with enfortumab vedotin has been accepted and granted Priority Review by the US FDA for patients with ...
Shares of uniQure N.V. (QURE) are falling about 37 percent on Tuesday morning after the company announced additional data from the ongoing Phase I/II studies of ifezuntirgene inilparvovec for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results